William Edward Boden MD
Professor, Cardiovascular Medicine
Lecturer in Medicine
150 S Huntington Avenue | (857) 364-4201william.boden@va.gov
Sections
Cardiovascular Medicine
Biography
I am ABIM board-certified in both Internal Medicine and the subspecialty of Cardiovascular Disease. Since 1979, I have held university appointments at Brown University, Wayne State University, Tufts New England Medical Center, Boston University, the University of Connecticut, State University of New York in Buffalo, and Albany Medical College. For the past 27 consecutive years, I have held leadership roles as either a Chief of cardiology or Chief of Medicine at both federal VA facilities and in the academic private sector, all of which have had strong affiliations with their respective academic health centers. In 2016, I re-joined the VA Boston MAVERIC Center as the Scientific Director, Clinical Trials Network, for the VA New England Healthcare System, and as the Research Lead Physician, for VISN 1.
I have extensive prior experience in clinical trials and comparative effectiveness research, and have served in a leadership capacity in several important national and international clinical trials, including as Study Chair for VA CSP-funded VANQWISH and COURAGE Trials, as Study Co-Chair of the NIH-funded AIM-HIGH Trial, and as a national co-PI for the NIH-funded ISCHEMIA Trial. My principal research interests include studies in stable ischemic heart disease, post-MI secondary prevention, acute coronary syndromes, and preventive cardiology.
Other Positions
Education
Medicine-Internal, MD, State University of New York at Brockport
Biology, BS, Le Moyne College
Publications
Gorog DA, de Silva R, Boden WE. The year in cardiovascular medicine 2024: the top 10 papers in ischaemic heart disease. Eur Heart J. 2025 Feb 25. PMID: 39995250.
Published on 12/20/2024Hashem C, Altin SE, Guyton JR, Boden WE. Nonlinearity of the inverse relationship between high-density lipoprotein (HDL) cholesterol and incident cardiovascular risk: Is it time to revisit the "HDL hypothesis"? J Clin Lipidol. 2024 Dec 20. PMID: 39934033.
Published on 12/17/2024Reynolds HR, Page CB, Shaw LJ, Berman DS, Chaitman BR, Picard MH, Kwong RY, Min JK, Leipsic J, Mancini GBJ, Budoff MJ, Hague CJ, Senior R, Szwed H, Bhargava B, Celutkiene J, Gadkari M, Bainey KR, Doerr R, Ramos RB, Ong P, Naik SR, Steg PG, Goetschalckx K, Chow BJW, Scherrer-Crosbie M, Phillips L, Mark DB, Spertus JA, Alexander KP, O'Brien SM, Boden WE, Bangalore S, Stone GW, Maron DJ, Hochman JS. Relationship Between Severity of Ischemia and Coronary Artery Disease for Different Stress Test Modalities in the ISCHEMIA Trial. Circ Cardiovasc Interv. 2024 Dec; 17(12):e013743. PMID: 39689188.
Published on 10/14/2024Weintraub WS, Boden WE. Achieving successful prevention of coronary artery disease: a worldwide call to action. Eur Heart J. 2024 Oct 14; 45(39):4197-4199. PMID: 39212225.
Published on 9/29/2024Boden WE, De Caterina R, Kaski JC, Bairey Merz N, Berry C, Marzilli M, Pepine CJ, Barbato E, Stefanini G, Prescott E, Steg PG, Bhatt DL, Hill JA, Crea F. Myocardial ischaemic syndromes: a new nomenclature to harmonize evolving international clinical practice guidelines. Eur Heart J. 2024 Sep 29; 45(36):3701-3706. PMID: 39211956.
Published on 9/29/2024Nurmohamed NS, Min JK, Anthopolos R, Reynolds HR, Earls JP, Crabtree T, Mancini GBJ, Leipsic J, Budoff MJ, Hague CJ, O'Brien SM, Stone GW, Berger JS, Donnino R, Sidhu MS, Newman JD, Boden WE, Chaitman BR, Stone PH, Bangalore S, Spertus JA, Mark DB, Shaw LJ, Hochman JS, Maron DJ. Atherosclerosis quantification and cardiovascular risk: the ISCHEMIA trial. Eur Heart J. 2024 Sep 29; 45(36):3735-3747. PMID: 39101625.
Published on 9/20/2024Ikemura N, Spertus JA, Nguyen D, Fu Z, Jones PG, Reynolds HR, Bangalore S, Bhargava B, Senior R, Elghamaz A, Goodman SG, Lopes RD, Pracon R, López-Sendón J, Maggioni AP, Kohsaka S, Roth GA, White HD, Mavromatis K, Boden WE, Rodriguez F, Hochman JS, Maron DJ. International Variation in Health Status Benefits in Patients Undergoing Initial Invasive Versus Conservative Management for Chronic Coronary Disease: Insights From the ISCHEMIA Trial. Circ Cardiovasc Qual Outcomes. 2024 Oct; 17(10):e010534. PMID: 39301726.
Published on 9/17/2024Boden WE, De Caterina R. ORBITA Trials Are Not Justification to Promote a PCI-First Strategy in Nonacute Myocardial Ischemic Syndromes. Circ Cardiovasc Qual Outcomes. 2024 Sep; 17(9):e011268. PMID: 39288214.
Published on 9/5/2024Guyton JR, Boden WE. Niacin, food intake and cardiovascular effects. Nat Med. 2024 Sep; 30(9):2444-2445. PMID: 39237629.
Published on 8/30/2024Boden WE, De Caterina R, Kaski JC, Bairey Merz N, Berry C, Marzilli M, Pepine CJ, Barbato E, Stefanini G, Prescott E, Steg PG, Bhatt DL, Hill JA, Crea F. Myocardial Ischemic Syndromes: A New Nomenclature to Harmonize Evolving International Clinical Practice Guidelines. Circulation. 2024 Nov 12; 150(20):1631-1637. PMID: 39210827.
Media Mentions
Published on 2/19/2024
Published on 5/9/2023
Enough PCI ‘Versus’ CABG—Time to Focus on Understudied Groups
Published on 1/25/2022
Optimal Medical Therapy for Stable Angina: Which Drugs? How Long?
Published on 6/28/2021
'Profound' Benefit Found for Staying on Meds Long After Coronary Revascularization
Published on 5/27/2021
Contentious ISCHEMIA Deep Dive: Extent of Revascularization Key?
Published on 5/19/2021
Meta-analysis Muses Over ISCHEMIA Message Had Trial Lasted Longer
Published on 1/5/2021
Stable CAD With High-Risk Anatomy Warrants PCI or CABG, APPROACH Suggests
Published on 6/26/2020
Economic value of alirocumab good if LDL greater than 100 mg/dL
Published on 1/25/2019
A Conversation With William E. Boden, MD, FACC, FAHA
Published on 2/23/2018
Some reasons not to rush into open-heart surgery
View full list of 10 media mentions.